Simon TG, et al. - In patients with nonalcoholic fatty liver disease (NAFLD), researches analyzed the impacts of aspirin on fibrosis using multivariable-adjusted logistic regression and multivariable-adjusted Cox proportional hazards modeling. The study sample consisted of 361 adults with biopsy-confirmed NAFLD examined every 3–12 months for incident advanced fibrosis defined using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score, and aspartate aminotransferase to platelet ratio indices). In a prospective study of patients with biopsy-proven NAFLD, daily aspirin use was linked to less severe histologic characteristics of NAFLD and nonalcoholic steatohepatitis, and lower risk for progression to advanced fibrosis with time.